Skip to content

    Protalix BioTherapeutics (PLX) stock price & financials

    View PLX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+58.7% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $17.96M
    $18.22M
    $10.11M
    $15.66M
    $17.85M
    -0.6%
    $9.12M
    -49.9%
    $33.75M
    +233.7%
    $19.90M
    +27.1%
    Strengthening
    Operating Profit
    $3.99M
    $7.21M
    -$4.14M
    $1.17M
    $2.13M
    -46.6%
    -$4.66M
    -164.6%
    $21.15M
    $4.67M
    +298.6%
    Strengthening
    Net Profit
    $3.24M
    $6.49M
    -$3.62M
    $164.0K
    $2.35M
    -27.2%
    -$5.50M
    -184.8%
    $18.32M
    $3.78M
    +2203.0%
    Strengthening
    EPS
    $0.04
    $-0.05
    $0.00
    $0.03
    -25.0%
    $0.23
    $0.05
    Strengthening
    Other Income
    -$148.0K
    $107.0K
    $413.0K
    -$511.0K
    $108.0K
    -$118.0K
    -210.3%
    -$5.0K
    -101.2%
    $188.0K
    Weakening
    Interest
    Depreciation
    Profit before Tax
    $3.84M
    $7.32M
    -$3.73M
    $661.0K
    $2.24M
    -41.7%
    -$4.78M
    -165.3%
    $21.14M
    $4.86M
    +635.2%
    Strengthening
    MarginsOPM
    22.2%
    39.6%
    -41.0%
    7.5%
    11.9%
    -46.3%
    -51.1%
    -229.0%
    62.6%
    23.5%
    +213.9%
    Weakening
    Tax
    15.8%
    11.2%
    3.0%
    75.2%
    -5.2%
    -132.8%
    -15.2%
    -235.6%
    13.4%
    +340.9%
    22.3%
    -70.4%
    Strengthening
    ReturnsROIC

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$37.81M$17.79M$18.27M$38.98M$17.11M$23.63M$19.76M$14.68M$27.42M
    Short-Term Investments
    Total Current Assets$52.98M$32.48M$55.72M$61.67M$44.88M$69.93M$60.08M$66.67M$92.22M
    Net PP&E$6.39M$10.95M$10.41M$9.92M$9.64M$10.88M$10.02M$12.58M$13.64M
    Goodwill
    Intangibles
    Total Assets$61.13M$45.39M$67.93M$73.67M$55.79M$84.43M$73.42M$82.35M$110.34M
    LiabilitiesTotal Current Liabilities$25.35M$40.17M$86.47M$33.18M$32.43M$45.53M$25.62M$26.52M$31.39M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$0$4.53M$4.47M$4.38M$4.17M$4.62M$4.03M$6.94M$7.54M
    Total Liabilities$114.01M$115.71M$94.97M$79.70M$66.43M$50.87M$30.21M$34.12M$38.93M
    EquityCommon Stock & APIC$15.0K$15.0K$35.0K$46.0K$54.0K$73.0K$76.0K$80.0K
    Retained Earnings-$322.55M-$340.83M-$347.35M-$374.93M-$389.86M-$381.55M-$378.39M-$385.00M
    Total Equity-$52.88M-$70.32M-$27.04M-$6.04M-$10.64M$33.57M$43.21M$48.23M$71.40M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$7.74M-$19.36M-$26.11M-$10.29M-$25.00M-$1.32M$8.67M-$11.99M$9.92M
    Cash from Investing-$591.0K-$883.0K-$19.95M$18.92M-$5.04M-$16.71M$4.22M-$2.37M-$1.03M
    Cash from Financing-$4.75M$0$46.47M$12.08M$8.24M$24.67M-$16.79M$9.33M$296.0K
    SummaryCapital Expenditure-$686.0K-$627.0K-$655.0K-$1.46M-$628.0K-$1.15M-$1.28M-$1.64M-$2.25M
    Free Cash Flow-$8.43M-$19.98M-$26.76M-$11.74M-$25.63M-$2.47M$7.39M-$13.63M$7.67M
    FCF Margin-24.6%-36.5%-42.5%-30.6%-53.8%-3.8%13.8%-25.8%9.5%

    Ratios